Infectious Disease
RSSArticles
-
Infectious Disease Alert Updates
Head and Neck Cancer Worse in HIV; Syphilis RPR May Fluctuate Before Treatment
-
Induction Therapy for HIV/AIDS-Related Disseminated Histoplasmosis with Single High-Dose Liposomal Amphotericin B
In a Phase II randomized clinical trial involving 118 participants in Brazil with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS)-related disseminated histoplasmosis, induction therapy with single high-dose (10 mg/kg) liposomal amphotericin B was safe and non-inferior as compared with standard dose (3 mg/kg) liposomal amphotericin B given once daily for 14 days.
-
Vaccination Against Mpox Is Effective
Two-dose vaccination with Jynneos is effective in the prevention of mpox (monkeypox), but a better vaccine is desirable, particularly for use in immunocompromised individuals.
-
Bird Flu: Is It Becoming a Threat to Humans?
A strain of influenza A virus that is highly pathogenic for birds is capable of infecting humans for whom it poses a potential risk as it continues to evolve and spread.
-
Idiopathic CD4 Lymphocytopenia
A study of 91 adults with idiopathic CD4 lymphocytopenia demonstrated increased risk of cancers and autoimmune disorders, as well as opportunistic infections.
-
What Is the Optimal Duration of Antibiotics for a Complicated UTI with Bacteremia?
An observational study of adults hospitalized with a complicated urinary tract infection and bacteremia found seven days of therapy was enough for the majority of cases when they received antibiotics with comparable intravenous and oral bioavailability.
-
The Current State of RSV
Respiratory syncytial virus is a common virus encountered in the ED, with myriad presentations and complications that clinicians must be able to identify and manage. The authors provide state-of-the-art diagnostic and management strategies for the acute care clinician.
-
Scientists Use Artificial Intelligence While Searching for ‘Superbug’ Solutions
Researchers enlisted the help of technology to find an antibiotic that could fight multidrug-resistant bacteria.
-
Respiratory Syncytial Virus Vaccine, Adjuvanted (Arexvy)
Arexvy can be administered to prevent lower respiratory tract disease caused by respiratory syncytial virus in patients age 60 years and older.
-
Infectious Disease Alert Updates
Immunocompromised Patients with Persistent COVID-19; Endemic Mycoses Are No Longer ‘-Demic’